2024 biotech funding tracker: recent highlights

June 2024:

• NXI Therapeutics (Switzerland): CHF 3.5 Million ($3.96 million) pre-seed | immunotherapies

January 2024: 

• Advesya (France): €23 million seed | cancer therapies
• Cumulus Oncology (United Kingdom): £9 million ($11.45 million) seed | cancer drug discovery
• DISCO Pharmaceuticals (Germany): EUR 20 million ($21.75 million) seed | drug discovery | map of small cell lung cancer surfaceome completed

February 2024: 

• Alys Pharmaceuticals (United States): $100M seed | immuno-dermatology | clinical in skin diseases
• Bioptimus (France): $35 million seed | AI-enabled drug discovery IsomAb (UK): £7.5 million ($9.46 million) seed | preclinical in peripheral arterial disease

March 2024:

• Relation Therapeutics (United Kingdom): $35 million seed | multi omics for drug discovery | discovery in osteoporosis

April 2024:

• Neurosterix (Switzerland): $63 million seed | allosteric modulator therapeutics | preclinical in schizophrenia
• Seamless Therapeutics (Germany) : $12.5 million seed | gene editing
• Outrun Therapeutics (United Kingdom) : $10 million seed | E3 ligase inhibitors | solid tumors
• RevOpsis (United States) : $16.5 million seed | eye disease therapies | IND-enabling studies in age-related macular degeneration
• Infinitopes (United Kingdom) : £12.8 million ($16.07 million) seed | cancer vaccines | preclinical in cancer

May 2024:

• OverT Bio (United States) : $16 million seed | cell therapies | preclinical in solid tumors
• Think Bioscience (United States): $6 million seed | small molecules | synthetic biology
• Hephaistos Pharma (France): €10.3 million ($11.16 million) seed | cancer immunotherapies | preclinical in cancer
• Limula (Switzerland): CHF 6.2 million ($6.78 million) seed | cell and gene therapies
• Radar Therapeutics (United States): $13.4 million seed | smart programmable medicines | preclinical in undisclosed targets
• Captain T Cell (Germany): €8.5 million ($9.2 million) seed | T cell therapies | preclinical

June 2024:

• ExpressionEdits (UK): $13 million seed | AI-enabled protein expression | candidate selection for preclinical studies
• Biophta (France): €6.5 million ($7.06 million) seed | eye disease therapies | preclinical in glaucoma
• Matter Bio (USA): $7 million seed | longevity drugs | preclinical in solid tumors
• Adcytherix (France): €30 million ($32.26 million) seed | antibody-drug-conjugates
• Ability Biologics (Canada): $18 million seed | targeted therapy discovery

July 2024: 

• Pan Cancer T (Netherlands) : €4.25 million ($4.65 million) seed extension | TCR therapies | preclinical in solid tumors
• Draupnir Bio (Denmark) : €12 million ($13.1 million) seed | targeted protein degradation | preclinical in heart disease

August 2024:

• Montara Therapeutics (United States): $8 million seed | neurological drugs | preclinical in neurological diseases
• Kano Therapeutics (United States): $7.1 million financing | genetic medicines
• Talus Bioscience (United States): $11.2 million seed | proteomics and AI | lead optimization stage in chordoma
• Diakonos Oncology (United States): $11.4 million seed | immunotherapies | phase 1 in glioblastoma
• Tern Therapeutics (United States): $15 million launch | gene therapies | phase 1/2 in CLN2 form of Batten disease
• Vironexis Biotherapeutics (United States): $26 million seed | gene therapies | IND-enabling studies in acute lymphoblastic leukemia

October 2024:

• Tolerance Bio (United States): $17.2 million seed | thymus-based therapies
• Shift Bioscience (United Kingdom): $16 million seed | AI cell simulation platform
• Booster Therapeutics (Germany): $15 million seed | small molecules
• Antiverse (United Kingdom): £3.5 million ($4.6 million) seed | AI antibody design platform
• Ikarovec (United Kingdom): £5 million seed | gene therapy | preclinical in geographic atrophy
• Archon Biosciences (United States): $20 million seed | antibody cage technology | preclinical stage

November 2024:

• Valora Therapeutics (United States): $30 million seed | immunotherapies
• Converge Bio (Israel): $5.5 million seed | AI-enabled drug discovery and development

October 2024:

• Epitopea (Canada, United Kingdom): $31 million pre-series A | cancer immunotherapies | preclinical in cancer

January 2024: 

• Claris Bio (United States): $57 million series A | corneal therapies | phase 1/2 clinical trial in neurotrophic keratitis
• Resalis Therapeutics (Italy): €10 million ($10.95 million) series A | non-coded RNA-based therapeutics | phase 1 in obesity
• OnCusp Therapeutics (United States): $100 million series A | oncology assets | preclinical in solid tumors
• Myrobalan Therapeutics (United States): $24 million series A | CNS disease therapies | IND-enabling in multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis
• Calluna Pharma (Norway): EUR 75 million ($81.71 million) series A | immune-related therapies | phase 1 in fibrosis
• Tr1X, Inc. (United States): $75 million series A | regulatory T cell-based therapies | phase 1 in graft versus host disease
• Granata Bio (United States): $14 million series A | women’s health | phase 3 in infertility
• AQEMIA (France): €60 million ($65.02 million) series A | AI-enabled drug discovery
• Imu Biosciences (United Kingdom): £11.5 million ($14.57 million) series A | immune discovery platform for precision medicines
• Sagimet Biosciences (United States): $112.5 million series A | phase 3 in nonalcoholic steatohepatitis
• COUR Pharmaceuticals (United States): $105 million series A | phase 2 in celiac disease
• Synnovation Therapeutics (United States): $102 million series A | small molecule therapies | clinical in solid tumors
• ZWI Therapeutics, Inc. (United States): $10 million series A | protein therapeutics | preclinical in refractory gout
• Moonwalk Biosciences (United States): $57 million series A | precision epigenetic medicines

February 2024: 

• Anbogen (Taiwan): $12.5 million series A | precision oncology | phase 2 in non-small cell lung cancer
• Basking Biosciences (United States): $55 million series A | acute thrombolytic therapy | phase 2 in acute ischemic stroke
• Latigo Biotherapeutics (USA): $135 million series A | non-opioid pain medicines | phase 1 in acute and chronic pain
• Firefly Bio (USA): $94 million series A | degrader antibody conjugates | preclinical in solid and liquid tumors
• Curve Therapeutics (UK): £40.5 million Series A | Small molecule drug discovery | Discovery stage in solid tumors
• Baseimmune (UK): $11.3 million in Series A | AI-enabled vaccine platform | Preclinical in coronavirus

March 2024:

• Kenai Therapeutics (USA): $82 million series A | stem cell therapy | preclinical in moderate to severe Parkinson’s disease.
• Tierra Biosciences (United States): $11.4 million series A | AI-derived protein synthesis
• Asgard Therapeutics (Sweden) | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer
• Mirador Therapeutics (United States) | $400 million series A | precision medicines
• Clasp Therapeutics (United States) | $150 million series A | T cell engagers
• Avenzo Therapeutics (United States) | $150 Million series A | cancer drugs | clinical in HR+ breast cancer
• Edgewood Oncology (United States) | $20 million series A | cancer drugs | phase 1 in acute myeloid leukemia

April 2024:

• Rhythm Pharmaceuticals (United States): $150 million series A | (MC4R) pathway-related treatments | phase 3 in obesity
• Diagonal Therapeutics (United States) : $128 million series A | antibody discovery | preclinical in hereditary hemorrhagic telangiectasia
• Seaport Therapeutics (United States) : $100 million series A | antidepressants and anxiolytics | phase 1 in major depression with anxiety
• DeepCure (United States) : $24.6 million series A-1 | small molecules | discovery in inflammatory and immunological conditions
• Corner Therapeutics (United States) : $54 million series A | cancer vaccines
• Rubedo Life Sciences (United States) : $40 million series A | chronic disease therapies | IND-enabling in chronic atopic dermatitis and chronic psoriasis
• Flindr Therapeutics (Netherlands) : €20 million ($21.38 million) series A | precision oncology | preclinical in ovarian cancer
• Brise Pharmaceuticals (China) : $20 million in pre-series A and series A | pain management | phase 1 in chronic low back pain

May 2024: 

• Reunion Neuroscience (United States) : $103 million series A | psychedelic treatments | phase 1 in postpartum depression
• Enlaza Therapeutics (United States) : $100 million series A | covalent protein technology | preclinical in cancer
• Delphia Therapeutics (United States) : $67 million series A | cancer therapies
• Latus Bio (United States) : $54 million series A | gene therapies | preclinical in CNS diseases
• Nabla Bio (United States): $26 million series A | protein design
• Uniquity Bio (United States): $300 million financing | immunology | phase 2 in chronic obstructive pulmonary disease
• Progentos Therapeutics (United States): $65 million series A | neuroscience | IND-enabling in depression
• YGION Biomedical (Austria): €15 million ($16.26 million) series A | cancer immunotherapies
• Adcendo (Denmark): €98 million ($106.3 million) series A | antibody-drug conjugates (ADC) | lead asset for soft tissue sarcoma
• SixPeaks Bio (Switzerland): $30 million series A | weight loss therapies

June 2024:

• Vilya (USA): $71 million series A | macrocyclic drugs
• Moleculent (Sweden): $26 million series A | mapping cellular communication
• Marea Therapeutics (USA): $190 million series A and B | cardiometabolic disease therapies | phase 2 in cardiovascular diseases
• Santa Ana Bio (USA): $168 million series A and B | precision medicine | IND-enabling stage in urticaria, food allergies, and asthma
• InduPro (USA): $85 million series A | protein therapeutics | preclinical in cancer
• Exsilio Therapeutics (United States): $82 million series A | gene therapies
• āshibio (United States): $40 million seed and series A | rare bone and connective tissue disorder therapies | clinical in fibrodysplasia ossificans progressiva
• Rapafusyn Pharmaceuticals (United States): $28 million series A | molecular glues | preclinical in acute kidney injury, cancer, and neuro-inflammatory disorders
• Augustine Therapeutics (Belgium): €17 million ($18.16 million) series A | neurological disorder therapeutics | preclinical in neuromuscular diseases
• Holoclara (United States): $16 million series A | worm-derived therapies | preclinical in allergic and autoimmune diseases

July 2024:

• Myricx Bio (United Kingdom) : £90 million ($114 million) series A | antibody drug conjugates | preclinical in cancer
• SciRhom (Germany) : €63 million ($68.19 million) series A | antibody therapies | preclinical in autoimmune diseases
• AusperBio (United States) : $37 million series A | targeted oligonucleotide therapies | phase 2 in hepatitis B
• Third Arc Bio (USA): $165 million series A | antibodies | preclinical in cancer and autoimmune diseases
• NGM Bio (USA): $122 million series A | biologics | phase 2 in primary sclerosing cholangitis
• Brenig Therapeutics (USA): $65 million series A | neurodegenerative diseases therapies | preclinical in Parkinson’s disease
• Renalys Pharma (Japan): ¥6 billion ($39 million) series A | kidney disease treatments | phase 3 in IgA nephropathy
• Rona Therapeutics (China): $35 million series A | RNA therapeutics | clinical in hypercholesterolemia
• ReviR Therapeutics (USA): $30 million series A | mRNA-modifying small molecules | IND-enabling studies in neurological diseases
• LTZ Therapeutics (USA/China): $20 million series A | immunotherapies | IND-enabling studies in B-cell lymphoma and autoimmune diseases
• Pinetree Therapeutics (USA): $17 million series A | targeted protein degraders
• Oisín Biotechnologies (USA): $15 million series A | genetic medicines

August 2024:

• Jade Biosciences (United States): $80 million launch | autoimmune disease therapies | preclinical in autoimmune disease
• AIRNA (United States/Germany): $60 million series A | RNA editing medicines | preclinical in alpha-1 antitrypsin deficiency
• Red Queen Therapeutics (United States): $55 million series A | antiviral therapies | phase 1 in COVID-19
• Borealis Biosciences (Canada): $150 million series A | RNA medicines
• Navigator Medicines (United States): $100 million series A | biologics development | phase 1 in autoimmune diseases
• Vandria (Switzerland): $30.7 million series A | mitochondrial therapeutics | IND-enabling studies for mild cognitive impairment
• Ambrosia Biosciences (United States): $16 million series A | metabolic disorder drug discovery
• Noetik (United States): $40 million series A | AI-driven cancer drug discovery

September 2024:

• Superluminal Medicines (United States): $120 million series A | drug discovery | preclinical stage
• NanoSyrinx (United Kingdom): £10 million ($13.08 million) financing | nanosyringes
• Nura Bio (United States): $68 million series A | small molecules | phase 1 in neurological diseases
• Radiant Bio (Canada): $35 million series A | engineered antibodies | preclinical in cancer
• GC Therapeutics (United States): $65 million series A | cell therapies
• Constructive Bio (United Kingdom): $58 million series A | biopolymers
• Brenus Pharma (France): $25 million series A | precision cancer vaccines | phase 1/2 in colorectal cancer
• LIfT BioSciences (United Kingdom): £10 million ($13.38 million) series A | innate cell therapies | preclinical in cancer
• VerImmune (United States): $4.5 million pre-series A | cancer vaccines | preclinical in cancer

October 2024:

• Kailera Therapeutics (United States): $400 million series A | obesity therapies | phase 2 in obesity and type 2 diabetes
• LoQus23 Therapeutics (United Kingdom): £35 million ($43 million) series A | small molecules | preclinical in Huntington’s disease
• Arda Therapeutics (United States): $43 million series A | targeted cell depletion therapies
• invIOs (Austria): €8.2 million ($8.93 million) series A | cancer immunotherapies | phase 1 in solid tumors
• Axonis Therapeutics (United States): $115 million series A | neuromedicines | phase 1 in refractory epilepsy, spinal cord injury, and chronic pain
• March Biosciences (United States): $28.4 million series A | CAR-T cell therapies | phase 2 in T cell lymphoma
• Blue Earth Therapeutics (United Kingdom): $76.5 million series A | radioligand therapies | phase 1 in prostate cancer

November 2024:

• Trace Neuroscience (United States): $101 million series A | genomic medicines | lead candidate in amyotrophic lateral sclerosis
• ATB Therapeutics (Belgium): €54 million ($56.96 million) series A | antibodies
• Freya Biosciences (Denmark): $10.4 million series A | women’s healthcare | phase 1 in vaginal dysbiosis
• Allink Biotherapeutics (China): $42 million series A | antibody-drug conjugates | preclinical in cancer

December 2024:

• Antag Therapeutics (Denmark): €80 million ($83.99 million) series A | GIPR antagonists | preclinical in obesity
• Tasca Therapeutics (United States): $52 million series A | small molecules | IND-enabling studies in cancer
• Akamis Bio (United States, United Kingdom): $60 million series A | cancer therapies | phase 1 in solid tumors

January 2024: 

• Vico Therapeutics (Netherlands): $60 million (€54 million) series B | RNA modulation | phase 1/2 in spinocerebellar ataxia type 3
• Full-Life Technologies (China, Belgium): $47.3 million series B | radionuclide drug conjugates | first-in-human trial in prostate cancer
• Avistone Biotechnology (China): 1 billion Chinese yuan (~$140 million) series B | targeted cancer drugs | clinical in non-small cell lung cancer
• HI-Bio (United States): $95 million series B | precision medicine | phase 2 in primary membranous nephropathy
• Stalicla (Switzerland): $17.4 million series B | neurodevelopmental disorder-specific precision medicine platform | phase 1b in autism spectrum disorder
• Cyrano Therapeutics (United States): $9 million series B | phase 2 in post-viral smell loss
• Ratio Therapeutics (United States): $50 million series B | radiotherapies | phase 1 in epithelial-derived cancers
• Comanche Biopharma (United States): $75 million series B | siRNA therapy | phase 1 in preeclampsia
• Enterprise Therapeutics (United Kingdom): £26 million ($33.1 million) series B | respiratory diseases therapies | phase 2a in cystic fibrosis

February 2024: 

• NeoPhore (United Kingdom): £9.6 million ($12.2 million) series B | immuno‑oncology therapies | drug discovery in solid tumors
• Attralus (United States): $56 million series B | pan-amyloid removal therapeutics | phase 1 in systemic amyloidosis
• ProfoundBio (United States): $112 million series B | antibody drug conjugates | phase 2 in solid tumors

March 2024:

• BlossomHill Therapeutics (USA): $100 million series B | small molecule medicines | preclinical in oncology.
• Nocion Therapeutics (USA): $62 million series B | small molecule medicines | phase 2b in chronic cough.
• Engrail Therapeutics (United States) | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder
• Tubulis (Germany) | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors
• Capstan Therapeutics (United States) | $175 million series B | RNA-based therapies | preclinical in autoimmune disorders

April 2024:

• Alterome Therapeutics (United States) : $132 million series B | small molecules | IND-enabling studies in breast and endometrial cancers
• TORL BioTherapeutics (United States) : $158 million series B-2 | antibody drug conjugates | early-stage clinical in CLDN 6+ tumors
• SynOx Therapeutics (Ireland, United Kingdom) : $75 million series B | monoclonal antibodies | phase 3 in tenosynovial giant cell tumor
• Pathios Therapeutics (United Kingdom) : $25 million series B | cancer therapies | preclinical in solid tumors
• Cerevance (United States) : $47 million series B | neurodegenerative disease therapies | phase 3 in Parkinson’s disease

May 2024:

• Qlaris Bio (United States) : $24 million series B | eye disease therapies | phase 1 in primary open angle glaucoma
• Attovia Therapeutics (United States): $105 million series B | antibody-based therapies | preclinical in immune-mediated diseases
• Brixton Biosciences (United States): $33 million series B | pain relief | preclinical in knee pain in osteoarthritis and after knee replacement surgery
• AltruBio (United States): up to $225 million in series B round | immune checkpoint enhancers | phase 2a in ulcerative colitis
• Pheon Therapeutics (United Kingdom): $120 million series B | antibody drug conjugates | preclinical in solid tumors
• LabGenius (United Kingdom): £35 million ($44.54 million) series B | machine learning-driven drug discovery
• Grey Wolf Therapeutics (United Kingdom): $50 million series B | antigen modulation therapies | phase 1/2 in solid tumors

June 2024:

• Gameto (USA): $33 million series B | women’s health | clinical development of in vitro maturation solution to improve IVF and egg freezing
• Elion Therapeutics (USA): $81 million series B | antifungal drugs | phase 1 in invasive aspergillosis
• Enveda Biosciences (USA): $55 million series B | AI-enabled drug discovery | preclinical in atopic dermatitis
• iOnctura (Switzerland): €80 million ($85.42 million) series B | cancer treatments | phase 2b/3 in uveal melanoma
• Vico Therapeutics (Netherlands): €54 million ($60 million) series B | neurological disease therapies | phase 1/2 in spinocerebellar ataxia type 3

July 2024: 

• Beacon Therapeutics (United States) : $170 million series B | gene therapies | phase 2/3 in X-linked retinitis pigmentosa
• Cardurion Pharmaceuticals (United States) : $260 million series B | cardiovascular disease therapies | phase 2 in heart failure
• GRO Biosciences (USA): $60 million series B | synthetic biology | preclinical in refractory gout
• Confo Therapeutics (Belgium): $60 million series B | G-protein coupled receptor treatments | phase 1 in peripheral pain

August 2024:

• Outpace Bio (United States): $144 million series B | cell therapies | IND-enabling studies in ovarian cancer
• Halda Therapeutics (United States): $126 million series B | cancer therapies | IND-enabling studies in prostate cancer
• IDRx (United States): $120 million series B | precision therapies | phase 1 in gastrointestinal stromal tumor
• Pathalys Pharma (United States): $105 million series B | kidney disease treatments | phase 3 in end-stage kidney disease

September 2024:

• OrsoBio (United States): $67 million series B | metabolic disease treatments | phase 1b in obesity
• PhoreMost (United Kingdom): $50 million series B | protein degradation | preclinical in solid tumors
• Vicebio (United Kingdom): $100 million series B | vaccines | phase 1 in respiratory syncytial virus
• Genespire (Italy): €46.6 million ($52.1 million) series B | gene therapies | preclinical in methylmalonic acidemia
• LongBio Pharma (China): undisclosed amount | antibody and fusion protein drugs | phase 1 in paroxysmal nocturnal hemoglobinuria
• Aktis Oncology (United States): $175 million series B | radiopharmaceuticals | clinical in solid tumors
• 858 Therapeutics (United States): $50 million series B | small molecules | phase 1 in solid tumors

October 2024:

• Seaport Therapeutics (United States): $225 million series B | neuropsychiatric medicines | phase 2 in major depressive disorder
• Terray Therapeutics (United States): $120 million series B | AI-driven drug discovery | preclinical in immunological diseases
• AvenCell (United States): $112 million series B | CAR-T cell therapy | phase 1/2 in acute myeloid leukemia

November 2024:

• Metsera (United States): $215 million series B | GLP1 medicines | phase 2 in obesity
• TRexBio (United States): $84 million series B | tissue regulation | phase 1 in autoimmune and inflammatory diseases
• Adcendo (Denmark): $135 million series B | antibody-drug conjugates | phase 1/2 in soft tissue sarcoma
• Cradle (Netherlands): $73 million series B | AI-powered protein engineering
  35Pharma (Canada): $53 million series C | activin inhibitors | phase 1 in pulmonary hypertension, cardiometabolic disease and obesity

December 2024:

• Nuvig Therapeutics (United States): $161 million series B | immunomodulatory therapies | phase 2 in chronic inflammatory demyelinating polyneuropathy
• Noema Pharma (Switzerland): CHF 130 million ($147 million) series B | central nervous system therapies | phase 2 in seizures in tuberous sclerosis complex
• Citryll (Netherlands): €85 million ($89.22 million) series B | neutrophil extracellular traps-targeting therapies | phase 1 in rheumatoid arthritis

January 2024:

• Accent Therapeutics (United States): $75 million series C | small molecule therapies | IND-enabling in breast, ovarian, colorectal, and endometrial cancers
• PRISM BioLab (Japan): 1.5 billion yen ($10.3 million) series C | drug discovery platform | phase 2 in cancer

February 2024: 

• Halia Therapeutics (United States): $30 million series C | anti-inflammatory therapeutics | phase 2 in myelodysplastic syndromes
• Frontier Medicines (USA): $80 million Series C | Precision medicine | Phase 1 in KRAS mutant cancers

March 2024:

• Alumis (United States): $259 million series C | precision immunology | phase 2 in psoriasis
• Sionna Therapeutics (United States): $182 million series C | small molecule therapies | phase 1 in cystic fibrosis
• Siolta Therapeutics (United States): $12 million series C | live biotherapeutics | phase 2 in atopic dermatitis, food allergy and allergic asthma

April 2024:

• Obsidian Therapeutics (United States) : $160.5 million series C | TIL therapy | phase 1 in melanoma
• Asher Bio (United States) : $55 million series C | immunotherapies | phase 1 in solid tumors
• Endeavor BioMedicines (United States) : $132.5 million series C | drug development | phase 2 in idiopathic pulmonary fibrosis

May 2024:

• Zenas BioPharma (United States) : $200 million series C | autoimmune therapies | phase 3 in IgG4-related disease
• Memo Therapeutics (Switzerland) : CHF 20 million ($22.01 million) series C extension | antibodies | phase 2/3 for BK virus infection in kidney transplant recipients
• BioVersys (Switzerland) : CHF 12.3 million ($13.54 million) series C | antibacterial products | phase 2 in carbapenem resistant Acinetobacter baumannii infections

• Bluejay Therapeutics (United States): $182 million series C | liver disease therapies | phase 2a in hepatitis D
• Lycia Therapeutics (United States): $106.6 million series C | protein degradation | preclinical in autoimmune and inflammatory conditions
• Ajax Therapeutics (United States): $95 million series C | JAK inhibitors | preclinical in myelofibrosis
• Aardvark Therapeutics (United States): $85 million series C | small molecules | phase 2 in obesity

June 2024:

• Bright Peak Therapeutics (Switzerland, United States): $90 million series C | protein drugs | preclinical in solid tumors
• Frontier Medicines (United States): $20 million series C | proteomics | phase 1 in cancer

July 2024: 

• Scorpion Therapeutics (United States) : $150 million series C | precision oncology | phase 1/2 in solid tumors
• Asceneuron (Switzerland) : $100 million series C | tau-targeting therapies | phase 2 in Alzheimer’s
• HepaRegeniX (Germany) : €15 million ($16.4 million) series C | regenerative therapies | phase 2a in liver regeneration
• Autobahn Therapeutics (USA): $100 million series C | small molecules | phase 1 in major depressive disorder

August 2024:

• MBX Biosciences (United States): $63.5 million series C | precision peptide therapies | phase 2 in hypoparathyroidism
• Healx (United Kingdom): $47 million series C | rare disease therapies | phase 2 in neurofibromatosis type 1

September 2024:

• ArsenalBio (United States): $325 million series C | CAR T cell therapies | phase 1 in ovarian cancer

October 2024:

• Nuclera (United Kingdom, United States): $75 million series C | protein expression
• Alpha-9 Oncology (Canada, United States): $175 million series C | radiopharmaceuticals
• Pathos AI (United States): $62 million series C | AI-enabled drug development | phase 1 in cancer
• Evommune (United States): $115 million series C | inflammatory disease therapeutics | phase 2 in chronic urticaria

November 2024:

• Enveda (United States): $130 million series C | drug discovery | phase 1 in atopic dermatitis

December 2024:

• Angitia Biopharmaceuticals (United States): $120 million series C | musculoskeletal disease therapeutics | phase 3 in spinal fusion

February 2024: 

• BioAge (United States): $170 million series D | metabolic disease drug discovery platform | phase 2 in obesity

June 2024: 

• Formation Bio (United States): $372 million series D | AI-based drug development | phase 2 in atopic dermatitis

July 2024:

• Element Biosciences (United States) : $277 million series D | DNA sequencing
• CatalYm (Germany) : $150 million series D | immunotherapy | phase 2b in solid tumors

September 2024: 

• Circle Pharma (United States): $90 million series D | cell-permeable macrocycles | IND-enabling studies in multiple solid tumors
• eGenesis (United States): $191 million series D | engineered organ development | IND-enabling in organ failure

October 2024:

• Agomab (Belgium): $89 million series D | small molecules | phase 2a in Crohn’s disease

November 2024:

• Alentis Therapeutics (Switzerland): $181.4 million series D | CLDN1 antibody-drug conjugates | phase 2 in kidney fibrosis

December 2024:

• Maze Therapeutics (United States): $115 million series D | small molecules | phase 2 in kidney disease

February 2024: 

• Neurona Therapeutics (United States): $120 million series E | cell therapies | phase 1/2 in focal epilepsies

March 2024:

• FogPharma (USA): $145 million series E | precision medicine | phase 1/2 in advanced or metastatic solid tumors.

June 2024:

• Alzheon (USA): $100 million series E | precision medicine | phase 3 in Alzheimer’s disease

July 2024:

• Cellectar Biosciences (USA): $19.4 million financing | cancer drugs | phase 2 in multiple myeloma

January 2024: 

• Immunic Therapeutics (United States): $240 million PIPE | small molecules | phase 3 in relapsing multiple sclerosis
• ORIC Pharmaceuticals (United States): $125 million PIPE | cancer treatments | phase 1b in multiple myeloma
• Kura Oncology (United States): $150 million PIPE | precision medicine | registration-directed trial in acute myeloid leukemia

February 2024: 

• Adverum Biotechnologies (United States): $127.5 million PIPE | gene therapy | phase 2 in wet age-related macular degeneration
• Silence Therapeutics (United Kingdom): $120 million PIPE | precision medicine | phase 2 in cardiovascular disease
• BioSenic (Belgium): €500,000 ($538,000) PIPE | regenerative and immune medicine | phase 2b in chronic graft vs host disease
• Mineralys Therapeutics (United States): $120 million PIPE | aldosterone synthase inhibitor | phase 2 in hypertension
• Cogent Biosciences (USA): $225 million PIPE | precision medicine | phase 3 in gastrointestinal stromal tumors
• Denali Therapeutics (USA): $500 million PIPE | Neurodegenerative disease therapeutics | Clinical in Hunter syndrome

March 2024:

• Applied Therapeutics (USA): $100 million PIPE | aldose reductase inhibitors | phase 3 in galactosemia.
• Regulus Therapeutics (United States): $100 million PIPE | RNA-based therapies | phase 1 in polycystic kidney disease
• Lexeo Therapeutics (United States): $95 million PIPE | genetic medicines | phase 1/2 in cardiac Friedreich’s ataxia
• Spyre Therapeutics (United States): $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease
• Cybin (Canada): $150 million PIPE | mental healthcare | phase 2 in major depressive disorder
• Unicycive (United States): $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia
• Elicio Therapeutics (United States): $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma

April 2024:

• Avalo (United States): $115.6 million PIPE | targeted therapies | phase 1 in hidradenitis suppurativa
• CervoMed (United States): $50 million PIPE | neurodegenerative disease therapies | phase 2b ion dementia
• Surrozen (United States): $17.5 million PIPE | targeted antibodies | phase 1 in severe alcoholic hepatitis
• Acrivon Therapeutics (United States) : $130 million PIPE | precision proteomics | phase 2 in ovarian, endometrial, and bladder cancers
• Protara Therapeutics (United States) : $45 million PIPE | cancer and rare disease therapies | phase 2 in non-muscle invasive bladder cancer
• Cullinan Therapeutics (United States) : $280 million PIPE | modality-agnostic targeted therapies | phase 3 in non-small cell lung cancer
• Eliem Therapeutics (United States, United Kingdom) : $120 million PIPE | nervous system disorder treatments | phase 1 in major depressive disorder
• Century Therapeutics (United States) : $60 million PIPE | stem cell therapies | phase 1 in blood cancers
• Leap Therapeutics (United States) : $40 million PIPE | cancer immunotherapies | phase 2 in gastric cancer
• Zura Bio (United States) : $112.5 million PIPE | immunotherapies | phase 2 in autoimmune and inflammatory diseases
• Korro Bio (United States) : $70 million PIPE | RNA editing | phase 1/2 in alpha-1 antitrypsin deficiency
• Benitec Biopharma (United States) : $40 million PIPE | gene therapies | phase 1b/2a in oculopharyngeal muscular dystrophy
• Cidara Therapeutics (United States) : $240 million PIPE | targeted immunotherapy | phase 2 in seasonal influenza

May 2024:

• Context Therapeutics (United States) : $100 million PIPE | solid tumor therapies | preclinical in multiple solid tumors
• Eledon Pharmaceuticals (United States) : $50 million PIPE | immune-modulating therapies | phase 2 in kidney transplantation
• Plus Therapeutics (United States) : up to $18 million PIPE | radiotherapies | phase 2b in recurrent glioblastoma

June 2024:

• Bionomics (Australia): up to $70 million PIPE | CNS disorders therapeutics | phase 2 in social anxiety disorder
• Akari Therapeutics (USA/UK): $7.6 million PIPE | autoimmune and inflammatory diseases therapeutics | phase 3 in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy
• Bio-Path (USA): $4 million PIPE | DNA therapies | phase 2 in acute myeloid leukemia
• Bio-Path (United States): $4 million PIPE | cancer therapies | phase 2 in acute myeloid leukemia
• Replimune (USA): $100 million PIPE | cancer treatments | phase 3 in melanoma
• Greenwich LifeSciences (USA): $2.5 million PIPE | immunotherapies | phase 3 in breast cancer

June 2024:

• NeuroBo Pharmaceuticals (United States): up to $70 million PIPE and registered direct offering | cardiometabolic disease therapies | phase 2a in metabolic dysfunction-associated steatohepatitis
• Eliem Therapeutics (United States, United Kingdom): $120 million PIPE | antibodies | phase 1 in systemic lupus erythematosus
• NeuroBo Pharmaceuticals (United States): up to $70 million PIPE and registered direct offering | cardiometabolic disease therapies | phase 2a in metabolic dysfunction-associated steatohepatitis

July 2024:

• Cartesian Therapeutics (United States): $130 million PIPE | cell therapies | phase 2 in myasthenia gravis
• Windtree Therapeutics (USA): $12.9 million PIPE | cancer and cardiovascular treatments | phase 2b in cardiogenic shock
• ProMIS Neurosciences (Canada/USA): up to $122.7 million PIPE | antibody therapeutics | phase 1 in Alzheimer’s disease
• Chemomab Therapeutics (Israel): $10 million PIPE | fibro-inflammatory therapeutics | phase 2 in primary sclerosing cholangitis

September 2024: 

• Summit Therapeutics (United States): $235 million PIPE | cancer therapies | phase 3 in non-small cell lung cancer
• Valneva (France): €60 million ($66.82 million) PIPE | vaccine development | phase 3 in Lyme disease

October 2024:

• IN8bio (United States): $12.4 million PIPE | T cell therapies | phase 1 in glioblastoma

November 2024:

• Bright Minds Biosciences (Canada): $35 million PIPE | neuroscience medicines | phase 2 in rare epilepsies
• Vittoria Biotherapeutics (United States): $25 million PIPE | cell therapies | phase 1 in lymphoma

January 2024:

• Dyne Therapeutics (United States): $300 million public offering | oligonucleotide therapeutics | phase 1/2 in myotonic dystrophy type 1
• Kymera Therapeutics (United States): $275 million public offering | targeted protein degradation | phase 2 in hidradenitis suppurativa and atopic dermatitis
• Praxis Precision Medicines (United States): $150 million public offering | precision medicine | clinical in pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy
• Dyne Therapeutics (United States): $345.1 million public offering | muscle disease therapies | clinical in myotonic dystrophy type 1
• XORTX (Canada): $2 million public offering | orphan disease indications | phase 2 in polycystic kidney disease
• Immatics (Germany): $175 million public offering | phase 1 in recurrent and refractory solid tumors
• Viridian Therapeutics (United States): $150 million public offering | antibody discovery and engineering | phase 3 in thyroid eye disease
• TransCode Therapeutics (United States): $7.25 million public offering | clinical in metastatic cancer
• Vaxcyte (United States): $750 million public offering | pneumococcal conjugate vaccines | phase 2 in pneumococcal disease
• CG Oncology (United States): $380 million IPO | targeted oncolytic immunotherapy | phase 3 in bladder cancer
• ArriVent Biopharma (United States): $175 million IPO | cancer therapeutics | phase 3 in non-small cell lung cancer
• Tourmaline Bio (United States): $172.5 million public offering | immune and inflammatory disease therapies | phase 2 in thyroid eye disease
• Panbela Therapeutics (United States): $9 million public offering | cancer therapies | phase 3 in pancreatic cancer

February 2024: 

• Vaxcyte (United States): $862.5 million public offering | vaccine technology | phase 2 in pneumococcal disease
• Vera Therapeutics (United States): $250 million public offering | immunologic disease therapeutics | phase 3 in IgA nephropathy
• Alto Neuroscience (United States): $128.6 million IPO | precision medicine | phase 2b in major depressive disorder
• Fractyl Health (United States): $110.0 million IPO | metabolic therapeutics | preclinical in obesity
• Corbus Pharmaceuticals (United States): $94.5 million public offering | precision oncology | IND clearance in solid tumors |
• Immix Biopharma (United States): $15 million public offering | cell therapy | phase 1b/2a in relapsed/refractory amyloidosis and relapsed/refractory multiple myeloma
• Kyverna Therapeutics (United States): $319 million IPO | cell engineering | phase 2 in B-cell driven autoimmune diseases
• Metagenomi (United States): $93.75 million IPO | precision genetic medicines | preclinical in hemophilia A
• PepGen (United States): $80.1 million public offering | gene therapies | phase 2 in Duchenne muscular dystrophy
• Tenax Therapeutics (United States): $9 million public offering | precision medicine | phase 3 in acute decompensated heart failure
• Larimar Therapeutics (USA): $150 million public offering | rare disease therapeutics | phase 1 in Friedreich’s ataxia
• Iovance Biotherapeutics (USA): $211 million underwritten offering | phase 3 in melanoma

March 2024: 

• Viking Therapeutics (USA): $550 million public offering | metabolic and endocrine disorder therapies | phase 2b in nonalcoholic steatohepatitis.
• BioVie (USA): $21 million public offering | liver and neurodegenerative disease therapeutics | phase 3 in Alzheimer’s disease.
• Apogee Therapeutics (United States): $420 million public offering | biologics | phase 1 in atopic dermatitis
• Eupraxia Pharmaceuticals (Canada): C$30 million ($22.23 million) public offering | precision medicine | phase 2 in osteoarthritis
• Cognition Therapeutics (United States): $11.5 million public offering | CNS therapies | phase 2 in mild to moderate Alzheimer’s disease
• Nkarta (United States): $240 million public offering | CAR NK cell therapies | phase 1 in lupus nephritis

April 2024: 

• Praxis Precision Medicines (United States): $200 million public offering | central nervous system therapies | phase 3 in essential tremor
• Boundless Bio (United States): $100 million initial public offering | precision oncology | phase 1 in oncogene-related cancers
• Stoke Therapeutics (United States): $125 million public offering | RNA-based medicines | phase 1/2 in Dravet syndrome
• Contineum Therapeutics (United States) : $110 million IPO | small molecules | phase 1 in idiopathic pulmonary fibrosis and multiple sclerosis
• Longeveron (United States) : $5.25 million public offering | cell therapies | phase 2 in hypoplastic left heart syndrome
• Nurix Therapeutics (United States) : $175 million public offering | small molecules and antibody therapies | phase 1 in B-cell cancers
• TScan Therapeutics (United States) : $150 million public offering | T cell receptor therapies | phase 1 in blood cancers
• Biohaven (United States) : $230 million public offering | neuroscience and cancer drugs | phase 3 in obsessive compulsive disorder
• Longeveron (United States) : $11.4 million public offering | cell therapies | phase 2 in hypoplastic left heart syndrome
• Mustang Bio (United States) : $4 million public offering | cell and gene therapies | phase 1 in non-Hodgkin lymphoma and chronic lymphocytic leukemia

May 2024:

• Soleno Therapeutics (United States): $138 million public offering | rare disease therapies | phase 3 in Prader-Willi syndrome
• Dyne Therapeutics (United States): $325.5 million public offering | muscle-targeted therapies | phase 1/2 in myotonic dystrophy type 1
• Monte Rosa Therapeutics (United States): $100 million public offering | molecular glue degraders | phase 1/2 in MYC-driven cancers
• Bicycle Therapeutics (United Kingdom): $555 million PIPE | precision medicine | phase 3 in urothelial cancer
• CARGO Therapeutics (United States): $110 million PIPE | cancer cell therapies | phase 2 in cancer

June 2024:

• Insmed (USA): $650 million public offering | rare disease therapeutics | phase 3 in MAC lung disease
• Structure Therapeutics (United States): $476 million public offering | chronic disease therapies | phase 2 in obesity
• Rapport Therapeutics (United States): $154 million IPO | small molecules | phase 1 in focal epilepsy
• ProKidney (United States): $130 million public offering | cell therapies | phase 3 in type 2 diabetes
• Annexon (United States): $125 million public offering | complement-mediated disease therapies | phase 3 in Guillain-Barré syndrome
• UroGen Pharma (USA): $107.5 million public offering | bladder cancer therapies | phase 3 in non-muscle invasive bladder cancer
• Rezolute (USA): $60 million public offering | rare disease therapies | phase 3 in congenital hyperinsulinism
• Alumis (United States): $250 million initial public offering | precision medicine | phase 2 in psoriasis

July 2024: 

• IDEAYA Biosciences (United States) : $263 million public offering | precision medicine | phase 2 in ocular melanoma
• Artiva Biotherapeutics (USA): $167 million IPO | cell therapies | phase 1 in systemic lupus erythematosus
• TransCode Therapeutics (USA): $3 million public offering | RNA therapeutics | clinical in metastatic tumors
• Verastem Oncology (USA): $55 million public offering | cancer therapies | phase 3 in recurrent low-grade serous ovarian cancer

August 2024:

• Ocugen (United States): $35 million public offering | gene and cell therapies | phase 3 in retinitis pigmentosa
• Mind Medicine (United States): $75 million public offering | neurological disease therapies | phase 2 in anxiety disorder
• Zevra Therapeutics (United States): $60 million public offering | rare disease therapeutics | NDA submitted for Niemann-Pick disease Type C
• Precigen (United States): $30 million public offering | gene and cell therapies | phase 2 in recurrent respiratory papillomatosis
• Ocugen (United States): $35 million public offering | gene and cell therapies | phase 3 in retinitis pigmentosa
• Actuate Therapeutics (United States): $22.4 million IPO | cancer therapies | phase 2 in pancreatic cancer
• Avidity Biosciences (United States): $300.1 million public offering | RNA therapeutics | phase 3 in myotonic dystrophy type 1
• Kymera Therapeutics (United States): $225 million public offering | targeted protein degradation | phase 2 in hidradenitis suppurativa and atopic dermatitis

September 2024:

• Vaxcyte (United States): $1.3 billion public offering | vaccines | phase 2 in pneumococcal disease
• Ionis (United States): $500.3 million public offering | RNA technology | phase 3 in Alexander disease
• BioCardia (United States): $7.2 million public offering | cell therapies | phase 3 in ischemic heart failure
• Nuvalent (United States): $350 million public offering | kinase inhibitors | phase 2 in non-small cell lung cancer
• Bicara Therapeutics (United States): $315 million initial public offering | bifunctional therapies | phase 1 in head and neck squamous cell carcinoma
• Zenas BioPharma (United States): $225 million initial public offering | immunology-based therapies | phase 3 in immunoglobin G4-related disease
• Viridian Therapeutics (United States): $225 million public offering | antibody therapeutics | phase 3 in thyroid eye disease
• Xencor (United States): $175 million public offering | engineered antibodies | phase 2 in prostate cancer
• MBX Biosciences (United States): $163.2 million initial public offering | precision peptide therapies | phase 2 in hypoparathyroidism
• Kairos Pharma (United States): $6.2 million initial public offering | cancer therapies | phase 2 in prostate cancer
• BioVie (United States): $3 million public offering | drug development | phase 2 in Alzheimer’s disease
• Wave Life Sciences (United States): $200 million public offering | RNA medicines | clinical in alpha-1 antitrypsin deficiency
• BioAge Labs (United States): $198 million initial public offering | metabolic disease therapies | phase 2 in obesity

October 2024: 

• Upstream Bio (United States): $255 million initial public offering | inflammatory disease therapies | phase 2 in severe asthma
• Immatics (Germany): $150 million public offering | cancer immunotherapies | phase 1b in cancer
• CAMP4 Therapeutics (United States): $75 million initial public offering | RNA-targeting therapeutics | phase 1 in urea cycle disorders
• Capricor Therapeutics (United States): $75 million public offering | exosome-based therapeutics | phase 3 in Duchenne muscular dystrophy
• Septerna (United States): $288 million IPO | GPCR-targeting therapies | phase 1 in hypoparathyroidism

November 2024:

• 89bio (United States): $125 million public offering | liver and cardiometabolic disease therapies | phase 3 in metabolic associated steatohepatitis
• Zai Lab (China, United States): $200 million public offering | drug development | phase 3 in non-small cell lung cancer
• Calidi Biotherapeutics (United States): $7.5 million public offering | immunotherapies | phase 1 in glioma
• Replimune (United States): $140 million public offering | cancer immunotherapies | phase 3 in melanoma
• Aptose Biosciences (Canada): $8 million public offering | cancer medicines | phase 2/3 in myeloid tumors
• BioXcel Therapeutics (United States): $7 million public offering | neuroscience | phase 3 in schizophrenia

December 2024:

• Revolution Medicines (United States): $600 million public offering | cancer medicines | clinical in pancreatic ductal adenocarcinoma
• Janux Therapeutics (United States): $350 million public offering | immunotherapies | phase 1 in metastatic castration-resistant prostate cancer
• Candel Therapeutics (United States): $80 million public offering | immunotherapies | phase 3 in prostate cancer

January 2024: 

• Fortress Biotech (United States): $11 million Post-IPO equity | drug development | phase 3 in metastatic cancer
• Vaxart (United States): $10 million Post-IPO equity | vaccine pills | phase 2 in Norovirus and COVID-19
• Effector Therapeutics (United States): $15 million Post-IPO equity | selective translation regulator inhibitors | phase 2b in non-small cell lung cancer
• Checkpoint Therapeutics (United States): $14 million Post-IPO equity | cancer therapies | awaiting approval for metastatic cutaneous squamous cell carcinoma drug
• Voyager Therapeutics (United States): $100 million Post-IPO equity | neurogenetic medicine | IND-enabling studies in Alzheimer’s disease
• Aptose (United States): $8.4 million Post-IPO equity | precision oncology | phase 1 in acute myeloid leukemia

February 2024: 

• NexImmune (United States): $3.67 million Post-IPO equity | T cell-mediated therapies | phase 1/2 in acute myeloid leukemia
• Jasper Therapeutics (United States): $50 million Post-IPO equity | antibody therapies | clinical in chronic spontaneous urticaria
• CRISPR Therapeutics (Switzerland): $280 million Post-IPO equity | CRISPR/Cas9 technology | clinical in CD19+ malignancies and autoimmune diseases
• Sensorion (France): €50.5 million ($54.04 million) Post-IPO equity | hearing loss restoration | phase in sudden sensorineural hearing loss
• Clearside Biomedical (United States): $15 million Post-IPO equity | eyecare and drug delivery | phase 3 in uveitic macular edema

March 2024:

• BioXcel Therapeutics (United States): $25 million Post-IPO equity | neuroscience and immuno-oncology | phase 3 in Alzheimer’s disease
• Sangamo Therapeutics (United States): $24 million Post-IPO equity | genomic medicine | preclinical in chronic neuropathic pain

April 2024:

• Vaccinex (United States): $1.5 million Post-IPO equity and PIPE | monoclonal antibodies | phase 2 in Alzheimer’s disease
• Oculis (Switzerland) : $59 million Post-IPO equity | eye care | phase 3 in diabetic macular edema
• Bio-Path Holdings (United States) : $1.2 million Post-IPO equity | RNA nanoparticle technology | phase 2 in blood cancers
• Belite Bio (United States) : $25 million Post-IPO equity | RBP4 antagonists | phase 3 in dry age-related macular disease and Stargardt disease
• INmune Bio (United States) : $9.7 million Post-IPO equity | immunology | phase 2 in Alzheimer’s disease

May 2024:

• ADC Therapeutics (Switzerland) : $105 million financing | antibody-drug conjugates | phase 3 in large B cell lymphoma
• Abeona Therapeutics (United States) : $75 million financing | gene therapies | phase 3 in recessive dystrophic epidermolysis bullosa
• Aileron Therapeutics (United States) : $40 million financing | orphan pulmonary and fibrosis treatments | phase 1b in idiopathic pulmonary fibrosis
• iTeos Therapeutics (United States, Belgium): $120 financing | cancer drugs | phase 2 in non-small cell lung cancer
• Allogene Therapeutics (United States): $110 million financing | CAR T therapies | phase 2 in large b-cell lymphoma
• Tevogen Bio (United States): up to $50 million in financing | T cell therapies | phase 1 in COVID-19
• Erasca (United States): $160 million financing | cancer therapies | phase 3 in melanoma
• Foghorn Therapeutics (United States): $110 million registered direct offering | precision medicine | phase 1 in acute myeloid leukemia
• MaaT Pharma (France): €18 Million ($19.51 million) offering | microbiome therapies | phase 3 in acute graft versus host disease
• Gt Biopharma (United States): $3.2 million registered direct offering | immunotherapy | phase 1 in acute myeloid leukemia and myelodysplastic syndromes

June 2024:

• Aptose Bioscience (USA): $4.43 million registered direct offering | precision oncology | phase 1/1b in myeloid tumors
• Mereo BioPharma (UK): $50 registered direct offering | rare disease therapies | phase 2 in osteogenesis imperfecta
• Longeveron (USA): $4.4 million financing | regenerative medicine | phase 2 in hypoplastic left heart syndrome
• Zealand Pharma (Denmark): DKK 6.26 billion ($900 million) equity offering | peptide drugs | phase 3 in obesityEntrada Therapeutics (United States): $100 million registered direct offering | intracellular therapeutics | phase 1 in Duchenne muscular dystrophy
• Ascentage Pharma (United States): $75 million equity investment | small molecules | phase 2 in chronic myeloid leukemia
• Mustang Bio (United States): $2.5 million registered direct offering | cell therapies | phase 1 in non-Hodgkin lymphoma and chronic lymphocytic leukemia
• Savara (United States): $100 million offering | rare respiratory disease therapies | phase 3 in autoimmune pulmonary alveolar proteinosis
• Vigil Neuroscience (United States): $40 million investment | neurodegenerative disease therapies | phase 2 in adult-onset leukoencephalopathy
• Eyenovia (United States): $5m registered direct offering | eyecare | phase 3 in pediatric myopia

July 2024:

• Checkpoint Therapeutics (United States): $12 million registered direct offering | immunotherapy | phase 3 in cutaneous squamous cell carcinoma completed
• Longeveron (USA): $9 million registered direct offering | regenerative medicine | phase 2a in hypoplastic left heart syndrome

August 2024:

• MeiraGTx (United States/United Kingdom): $50 million offering | genetic medicines | phase 2 in xerostomia
• TC BioPharm (United Kingdom): $2 million registered direct offering | T cell therapies | phase 1 in acute myeloid leukemia
• Anaptys (United States): $100 million registered direct offering | immunology therapeutics | phase 2 in atopic dermatitis

September 2024:

• INmune Bio (United States): $13 million registered direct offering | immune system-targeted therapies | phase 2 in early Alzheimer’s disease
• Ventyx Biosciences (United States): $27 million financing | small molecules | phase 2 in Parkinson’s disease, obesity, and other neuroinflammatory diseases
• Fortress Biotech (United States): $8 million registered direct offering and PIPE | drug development | phase 3 in cancers

October 2024:

• Bright Minds Biosciences (Canada): $35 million private placement | central nervous system therapies | phase 2 in rare epilepsies
• BioVie (United States): $6.66 million ($6.49 million) registered direct offering and concurrent private placement | liver disease and neurological therapies | clinical in liver cirrhosis
• CNS Pharmaceuticals (United States): $3 million registered direct offering | anti-cancer drugs | phase 2 in glioblastoma multiforme
• Calidi Biotherapeutics (United States): $2 million registered direct offering and private placement | immunotherapies | phase 1 in glioma

November 2024:

• Cidara Therapeutics (United States): $105 million private placement | immunotherapies | phase 2 in seasonal influenza
• Aizen Therapeutics (United States): $13 million financing | mirror peptides
• TransCode Therapeutics (United States): $8 million private placement | cancer medicines | phase 1 in pancreatic cancer

December 2024:

• Olema Oncology (United States): $250 million private placement | cancer medicines | phase 3 in breast cancer
• Senti Biosciences (United States): $37.6 million private placement | cell and gene therapies | phase 1 in acute myeloid leukemia
• Serina Therapeutics (United States): $10 million financing | small molecules | preclinical in Parkinson’s disease
• Kane Biotech (Canada): $3,000,000 private placement | biofilm research
• Cardiff Oncology (United States): $40 million registered direct offering | small molecules | phase 2 in metastatic colorectal cancer
• Sonnet BioTherapeutics (United States): $3.9 million registered direct offering and private placement | cytokine-derived therapies | phase 1 in solid tumors

January 2024: 

• BridgeBio Pharma (United States): up to $1.25 billion in Post-IPO Debt | genetic disease therapies | phase 3 in transthyretin amyloidosis

May 2024:

• Adaptimmune (United States/United Kingdom): up to $125 million debt financing | T-cell therapies | FDA review for synovial sarcoma

June 2024:

• Tevogen Bio (United States): up to $50 million financing | immunotherapies | clinical stage in COVID-19

July 2024:

• Trevena (United States) : $2 million financing | central nervous system disorder therapies | phase 1 in diabetic neuropathic pain and epilepsy

August 2024:

• Arrowhead Pharmaceuticals (United States): $500 million strategic financing | RNA technology | phase 3 in severe hypertriglyceridemia

September 2024:

• Jazz Pharmaceuticals (Ireland): $850 million private offering | cancer and neurological disorder therapies | phase 3 in gastroesophageal adenocarcinoma

October 2024:

• Leal Therapeutics (United States): $45 million financing | CNS therapeutics | IND-enabling studies in amyotrophic lateral sclerosis

November 2024:

• Geron (United States): up to $375 million in royalty and debt financings | telomerase inhibition | phase 3 in myelofibrosis
• Disc Medicine (United States): $200 million non-dilutive debt financing | bleeding disorder therapies | phase 2 in erythropoietic porphyrias

April 2024:

• Sensorion (France) : €15 million ($16.29 million) reserved offering | hearing disorder therapies | phase 2 in sudden sensorineural hearing loss

July 2024: 

• Mission Therapeutics (United Kingdom): $5.2 million grant | small molecules | phase 2 in heart failure
• Tiziana (United States): $3.4 million financing | neurodegenerative disease therapies | phase 2 in multiple sclerosis

August 2024:

• Shinobi Therapeutics (United States/Japan): $59 million grant | iPS cell therapies | preclinical in solid tumors

January 2024: 

• Remix Therapeutics (United States): $60 million | RNA therapeutics | phase 1 in adenoid cystic carcinoma
• C4 Therapeutics (United States): $25 million | targeted protein degradation | clinical in multiple myeloma & non-Hodgkin’s lymphoma
• DelSiTech (Finland): €10 million ($10.88 million) | drug delivery | clinical in chronic hepatitis B
• Locus Biosciences (United States): $23.9 million  | precision medicine | phase 2 in urinary tract infections
• Eyconis (United States): launches with $150 million Series unknown | eyecare therapies

March 2024:

• Mission Therapeutics (United Kingdom): £25.2 million ($​​32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury
• Profluent (United States): $35 million financing | AI-enabled protein design

April 2024:

• Sutro Biopharma (United States): $75 million | antibody drug conjugates | phase 2/3 in ovarian cancer
• EnteroBiotix (United Kingdom) : £27 million ($34.27 million) financing | microbiome medicines | phase 2 in irritable bowel syndrome
• Metsera (United States) : $290 million | obesity and metabolic disease medicines | phase 1 in obesity
• Theolytics (United Kingdom) : £19 million ($24.5 million) financing | preclinical in ovarian cancer
• Xaira Therapeutics (United States) : $1 billion financing | AI-based drug discovery and development
• 4P-Pharma (France) : €15 million ($16.1 million) financing | drug development | phase 1 in osteoarthritis
• Locate Bio (United Kingdom) : £9.2 million ($11.55 million) financing | orthobiologics | preclinical in chronic low back pain

May 2024:

• BridgeBio (United States) : $200 million private financing | genetic disease and cancer therapies | phase 3 in transthyretin amyloidosis
• X4 Pharmaceuticals (United States): $125 million financing | rare disease therapies | phase 2 in chronic neutropenic disorders
• Cassava Sciences (United States): over $125 million | neuroscience | phase 3 in Alzheimer’s disease
• Hercules CM NewCo (China): $400 million financing | obesity drugs | phase 2 in type 2 diabetes and obesity
• Genelux Corporation (United States): $27.5 million financing | immuno-oncology | phase 3 in ovarian cancer

June 2024:

• Cinrx Pharma (USA): $73 million financing | drug development | phase 2 in obesity
• ITM (Germany): €188 million ($202.13 million) financing | radiopharmaceuticals | phase 3 in neuroendocrine tumors
• NeOnc Technologies (United States): $18.5 million financing | central nervous system therapeutics | phase 2 in brain cancer

July 2024:

• SmartCella (Sweden) : €50 million ($54.1 million) financing | drug delivery
• Abiologics (USA): $50 million financing | biologics
• Ancilia Biosciences (USA): $4.2 million financing | bacterial therapies
• CellCentric (UK): $35 million financing | small molecules | phase 1/2 in multiple myeloma

September 2024:

• ILC Therapeutics (United Kingdom): £2.5 million ($3.27 million) financing | hybrid interferons | preclinical in respiratory syncytial virus

October 2024:

• Be Bio (United States): $82 million financing | engineered B cell therapies | phase 1/2 in hemophilia B

December 2024:

• nChroma Bio (United States): $75 million launch | genetic medicines | preclinical in chronic hepatitis B and hepatitis D coinfection
• bit.bio (United Kingdom): $30 million financing | cell programming | preclinical in acute liver diseases
• Indapta Therapeutics (United States): $22.5 million financing | cell therapies | phase 1 in non-Hodgkin’s lymphoma and multiple myeloma